Clinical Trial Update: The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update on Ramosetron (5-HT3 receptor antagonist) evaluating safety and efficacy for fecal incontinence (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fecal Incontinence

Drugs mentioned

• Ramosetron (ramosetron)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Fecal Incontinence | Phase 2, Phase 3 | Status: UNKNOWN